Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900834 · ClinicalTrials.gov registry record
Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 61
- Enrollment target
NCT01900834: Completed study, sponsored by Novo Nordisk A/S.
NCT01900834 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900834 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
Study Summary
This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic subjects over a one year period.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-10 |
What the finished NCT01900834 record still lists
NCT01900834 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT01900834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01900834 about?
NCT01900834 is a clinical study titled "Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period". This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic subjects over a one year period.
What is the current status of trial NCT01900834?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2013-07. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01900834?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT01900834?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia